Drug maker GSK is buying a biotechnology company developing vaccines for respiratory and infectious diseases that generate multiple immune responses. . . . → Read More: GSK Acquires Advanced Vaccine Biotech in $3.3B Deal
|
|||||
Drug maker GSK is buying a biotechnology company developing vaccines for respiratory and infectious diseases that generate multiple immune responses. . . . → Read More: GSK Acquires Advanced Vaccine Biotech in $3.3B Deal A collaboration between developers of protein analytics and test-strip diagnostics aims to create a quicker, more sensitive, easy-to-use Covid-19 detection test. . . . → Read More: Partnership Developing Faster, Sensitive Covid-19 Test A creator of game therapies for cognitive impairments is becoming a publicly-traded company through a special purpose acquisition company or SPAC. . . . → Read More: Digital Mental Therapy Company to Go Public in Merger Global drug maker Novo Nordisk is acquiring biotechnology company Dicerna Pharmaceuticals Inc. in an all-cash deal valued at $3.3 billion. . . . → Read More: Novo Nordisk Buys RNA Biotech in $3.3B Deal A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger. . . . → Read More: Synthetic Antibody Company Goes Public in $230M Merger A company producing synthetic RNA for agricultural and biomedical applications is now a public company after a special-purpose acquisition. . . . → Read More: RNA Manufacturer Goes Public in $282M Merger Drug maker Bayer is acquiring a company discovering new therapies with a technology that reveals complex protein targets considered difficult to address. . . . → Read More: Protein Chemistry Biotech Acquired in $2B Deal Drug maker Sanofi is purchasing biotechnology company Translate Bio, a developer of messenger RNA vaccines and therapies, and a long-time collaborator. . . . → Read More: Sanofi Acquires mRNA Developer in $3.2B Deal A new enterprise discovering treatments for neurodegenerative diseases is merging with another start-up and raising $73 million its first venture round. . . . → Read More: Neuro Disease Start-Up Raises $73M in Early Funds A company developing synthetic biology and engineering tools for biotechnology is becoming a public company through a special-purpose acquisition. . . . → Read More: Synthetic Bio Company Goes Public in $2.5B Merger |
|||||
Copyright © 2024 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |